Triple
T22796980
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | onasemnogene abeparvovec |
E564274
|
entity |
| Predicate | tradeName |
P1500
|
FINISHED |
| Object | Zolgensma |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Zolgensma | Statement: [onasemnogene abeparvovec, tradeName, Zolgensma]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Zolgensma Context triple: [onasemnogene abeparvovec, tradeName, Zolgensma]
-
A.
AveXis
AveXis is a biotechnology company best known for developing the gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy.
-
B.
onasemnogene abeparvovec
chosen
Onasemnogene abeparvovec is a gene therapy medication that delivers a functional copy of the SMN1 gene to treat infants and young children with certain forms of spinal muscular atrophy.
-
C.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
D.
Trikafta
Trikafta is a breakthrough combination therapy for cystic fibrosis that targets the underlying genetic defect to improve lung function and reduce symptoms in eligible patients.
-
E.
GIVLAARI (givosiran)
GIVLAARI (givosiran) is an RNA interference (RNAi) therapeutic used to reduce the frequency of attacks in adults with acute hepatic porphyria.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2458185f88190b0045227ee420411 |
completed | April 17, 2026, 2:36 p.m. |
| NER | Named-entity recognition | batch_69f17cd9b3c0819096050f43a829ec0d |
completed | April 29, 2026, 3:36 a.m. |
Created at: April 17, 2026, 3:30 p.m.